NCT05263934

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

A 52-week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-centre, Non-inferiority Study to Investigate the Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Receiving Standard of Care (SoC) Therapy

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 163 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.

Conditions

• Eosinophilic Granulomatosis With Polyangiitis

Interventions

Type	Name	Description
BIOLOGICAL	Depemokimab	Depemokimab will be administered
BIOLOGICAL	Mepolizumab	Mepolizumab will be administered
DRUG	Placebo matching mepolizumab	Placebo matching to mepolizumab will be administered.
DRUG	Placebo matching depemokimab	Placebo matching to depemokimab will be administered.

Timeline

• Start date: 2022-07-14
• Primary completion: 2026-09-29
• Completion: 2026-10-27
• First posted: 2022-03-03
• Last updated: 2025-11-20

Locations

76 sites across 20 countries: United States, Argentina, Austria, Belgium, Brazil, Canada, China, France, Germany, Hungary, Israel, Italy, Japan, Netherlands, Poland, Portugal, South Korea, Spain, Sweden, United Kingdom

Regulatory

• FDA-regulated drug study